ArticlePloS one2026
Therapeutic effect and mechanism of different doses of aspirin on preterm delivery in pregnant mice.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreterm birth is a major cause of perinatal mortality and complications, with inflammation being a key contributing factor. Current treatments, like uterine contraction inhibitors and antibiotics, are unsatisfactory. Aspirin, a cyclooxygenase inhibitor, shows promise in treating infectious preterm labor but has limited in vivo studies and an unclear mechanism.
methodsIn this study, a mouse model of infectious preterm birth was established via lipopolysaccharide (LPS) injection, and the aspirin doses used in these animals were converted from the recommended human doses by the body surface area method, with the high-dose and low-dose groups set at 0.78 mg/kg and 0.21 mg/kg, respectively. ELISA detected inflammatory factors TNF-α, IL-1β, IL-6 in serum, amniotic fluid and placenta. WST-8 kit and TBA method measured serum SOD activity and MDA content, respectively. DTNB colorimetric method analyzed glutathione content in liver and placenta. Western blot detected MyD88, IκB, p-IκB and nucleus NF-κB p65 protein expression in uterine tissues.
resultsResults showed the 75 μg/kg LPS group had a 91.7% preterm birth rate and 4.67% stillbirth rate. Low-dose (66.7%) and high-dose (41.6%) aspirin reduced preterm birth and increased live birth rates, with significant intergroup differences (P < 0.05). Aspirin lowered LPS-induced TNF-α, IL-1β, IL-6 in serum, amniotic fluid and placenta, regulated oxidative stress, reversed MyD88/p-IκB overexpression and reduced p65 nuclear translocation. TLR4/NF-κB inhibitors downregulated these factors and nuclear NF-κB p65/p-IκB. Additionally, we found that inflammatory LPS induced abnormal fetal mouse skeletal development (e.g., malformation and deficiency), which was ameliorated by aspirin exposure.
conclusionAspirin may ameliorate preterm birth by up-regulating TLR4/NF-κB pathway, laying theoretical basis for aspirin clinical application in preterm birth.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.